Naproxen Sodium; Sumatriptan Succinate Patent Expiration
Naproxen Sodium; Sumatriptan Succinate is Used for the treatment of migraines. It was first introduced by Currax Pharmaceuticals Llc
Naproxen Sodium; Sumatriptan Succinate Patents
Given below is the list of patents protecting Naproxen Sodium; Sumatriptan Succinate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Treximet |
US7332183 (Pediatric) | Multilayer dosage forms containing NSAIDs and triptans | Apr 02, 2026 | Currax |
| Treximet | US7332183 | Multilayer dosage forms containing NSAIDs and triptans | Oct 02, 2025 | Currax |
| Treximet |
US5872145 (Pediatric) | Formulation of 5-HT agonist and NSAID for treatment of migraine |
Feb 14, 2018
(Expired) | Currax |
| Treximet |
US6060499 (Pediatric) | Anti-migraine methods and compositions using 5-HT agonists with long-acting NSAIDs |
Feb 14, 2018
(Expired) | Currax |
| Treximet |
US6586458 (Pediatric) | Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs |
Feb 14, 2018
(Expired) | Currax |
| Treximet |
US8022095 (Pediatric) | Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs |
Feb 14, 2018
(Expired) | Currax |
| Treximet | US5872145 | Formulation of 5-HT agonist and NSAID for treatment of migraine |
Aug 14, 2017
(Expired) | Currax |
| Treximet | US6060499 | Anti-migraine methods and compositions using 5-HT agonists with long-acting NSAIDs |
Aug 14, 2017
(Expired) | Currax |
| Treximet | US6586458 | Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs |
Aug 14, 2017
(Expired) | Currax |
| Treximet | US8022095 | Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs |
Aug 14, 2017
(Expired) | Currax |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Naproxen Sodium; Sumatriptan Succinate's patents.
Latest Legal Activities on Naproxen Sodium; Sumatriptan Succinate's Patents
Given below is the list recent legal activities going on the following patents of Naproxen Sodium; Sumatriptan Succinate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical
| 28 Oct, 2019 | US8022095 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 19 Aug, 2019 | US7332183 |
| Maintenance Fee Reminder Mailed Critical
| 13 May, 2019 | US8022095 |
| Request for Trial Denied Critical
| 06 May, 2016 | US7332183 |
| Petition Requesting Trial | 12 Nov, 2015 | US7332183 |
| Email Notification Critical
| 04 Sep, 2012 | US7332183 |
| Change in Power of Attorney (May Include Associate POA) Critical
| 04 Sep, 2012 | US7332183 |
| Correspondence Address Change Critical
| 01 Sep, 2012 | US7332183 |
| Email Notification Critical
| 21 Sep, 2011 | US8022095 |
| Recordation of Patent Grant Mailed Critical
| 20 Sep, 2011 | US8022095 |
Naproxen Sodium; Sumatriptan Succinate's Family Patents
